Recent Advances on 5‐Lipoxygenase Biochemistry


5‐Lipoxygenase (5‐LOX) catalyses two steps in the biosynthesis of leukotrienes (LTs), lipid mediators of inflammation derived from arachidonic acid. LTs function in normal host defence, and have pathophysiological roles in chronic inflammatory diseases, as asthma and atherosclerosis. Also, possible effects of 5‐LOX products in relation to tumorigenesis have been described. 5‐LOX is also involved in the biosynthesis of anti‐inflammatory/pro‐resolving lipoxins. 5‐LOX is mainly expressed in myeloid and lymphoid cells and its expression is upregulated during cell differentiation. Cellular 5‐LOX activity is regulated in a complex manner and depends on cellular localisation, phosphorylation, the intracellular calcium concentration and the redox status of the cell. Thus, insight regarding the biochemistry of 5‐LOX is relevant for better understanding of normal physiology, and for development of pharmacotherapy.

Key Concepts:

  • Lipoxygenases oxygenate polyunsaturated fatty acids.

  • 5‐LOX produces 5‐HPETE, leukotrienes and together with other dioxygenases lipoxins.

  • The regulatory C2‐like domain binds Ca2+, diacylglycerols and phosphatidylcholine and regulates the activity of the catalytic domain.

  • 5‐LOX interacts with various proteins such as FLAP, CLP and Dicer.

  • The 5‐lipoxygenase pathway is part of the innate immune system.

  • 5‐LOX products are involved in inflammation, allergic reactions, development of cardiovascular disease as well as certain types of cancer.

Keywords: 5‐lipoxygenase; leukotrienes; lipoxins; 5‐HETE; arachidonic acid; C2‐like domain; nonhaem iron

Figure 1.

Conversion of AA to LTs and 5‐HETE.

Figure 2.

(a) Model of human wildtype 5‐LOX derived from the crystal structure of stable 5‐LOX (PDB: 3o8y). Grey, C2‐like domain; green, catalytic domain; orange, ATP‐binding sites; red, active site iron; dark blue, Ser phosphorylation sites; light blue, Tyr phosphorylation sites; purple, Ca2+ binding site. (b) Model of 5‐LOX dimer; orange, ATP‐binding sites. (c) Model structure of the CLP‐5‐LOX complex. Generated from a model structure of 5‐LOX and a structure of CLP (PDB: 1WNJ), as described in Esser et al. (). Grey, 5‐LOX C2‐like β‐sandwich; Blue, 5‐LOX catalytic domain. Trp residues 13, 75 and 102 are in orange. The CLP backbone is in purple, with Lys131 indicated by green spheres.

Figure 3.

Ca2+‐induced formation of 5‐H(P)ETE and LTA4 by 5‐LOX in presence of scaffold factors CLP (stoichiometry 1:1) and/or phosphatidylcholine (PC, 25 µg ml−1).

Figure 4.

Regulation of cellular 5‐LOX activity. 5‐LOX resides as soluble protein in the nucleoplasm or the cytsol, depending on the cell type and/or the phosphorylation status at Ser271 or Ser523. Upon cell stimulation soluble 5‐LOX binds Ca2+ and may become phosphorylated, and then translocates to the nuclear envelope where it binds to the outer or inner nuclear membrane via Ca2+ close to membrane‐integrated FLAP. AA liberated by cPLA2 is transferred via FLAP to 5‐LOX producing LTA4 that is converted by LTC4S (cytosolic side) or LTA4H (intranuclear) to LTC4 or LTB4, respectively.



Abramovitz M, Wong E, Cox ME et al. (1993) 5‐Lipoxygenase‐activating protein stimulates the utilization of arachidonic acid by 5‐lipoxygenase. European Journal of Biochemistry 215: 105–111.

Albert D, Buerkert E, Steinhilber D et al. (2003) Induction of 5‐lipoxygenase activation in polymorphonuclear leukocytes by 1‐oleoyl‐2‐acetylglycerol. Biochimica et Biophysica Acta 1631: 85–93.

Albert D, Pergola C, Koeberle A et al. (2008) The role of diacylglyceride generation by phospholipase D and phosphatidic acid phosphatase in the activation of 5‐lipoxygenase in polymorphonuclear leukocytes. Journal of Leukocyte Biology 83: 1019–1027.

Allard JB and Brock TG (2005) Structural organization of the regulatory domain of human 5‐lipoxygenase. Current Protein & Peptide Science 6: 125–131.

Bair AM, Turman MV, Vaine CA et al. (2012) The nuclear membrane leukotriene synthetic complex is a signal integrator and transducer. Molecular Biology of the Cell 23: 4456–4464.

Borgeat P, Hamberg M and Samuelsson B (1976) Transformation of arachidonic acid and homo‐γ‐linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. Journal of Biological Chemistry 251: 7816–7820.

Borgeat P and Samuelsson B (1979) Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proceedings of the National Academy of Sciences of the USA 76: 2148–2152.

Brock TG (2008) Capturing proteins that bind polyunsaturated fatty acids: demonstration using arachidonic acid and eicosanoids. Lipids 43: 161–169.

Bürkert E, Arnold C, Hammarberg T et al. (2003) The C2‐like beta‐barrel domain mediates the Ca2+‐dependent resistance of 5‐lipoxygenase activity against inhibition by glutathione peroxidase‐1. Journal of Biological Chemistry 278: 42846–42853.

Chen XS, Zhang YY and Funk CD (1998) Determinants of 5‐lipoxygenase nuclear localization using green fluorescent protein 5‐lipoxygenase fusion proteins. Journal of Biological Chemistry 273: 31237–31244.

Di Francesco A, Arosio B, Gussago C et al. (2013) Involvement of 5‐lipoxygenase in Alzheimer's disease: a role for DNA methylation. Journal of Alzheimer's Disease 37: 3–8.

Dincbas‐Renqvist V, Pepin G, Rakonjac M et al. (2009) Human Dicer C‐terminus functions as a 5‐lipoxygenase binding domain. Biochimica et Biophysica Acta 1789: 99–108.

Eek P, Jarving R, Jarving I et al. (2012) Structure of a calcium‐dependent 11R‐lipoxygenase suggests a mechanism for Ca2+ regulation. Journal of Biological Chemistry 287: 22377–22386.

Esser J, Gehrmann U, D'Alexandri FL et al. (2010) Exosomes from human macrophages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte migration. Journal of Allergy and Clinical Immunology 126: 1032–1040.

Esser J, Rakonjac M, Hofmann B et al. (2009) Coactosin‐like protein functions as a stabilizing chaperone for 5‐lipoxygenase: role of tryptophan 102. Biochemical Journal 425: 265–274.

Ferguson AD, McKeever BM, Xu S et al. (2007) Crystal structure of inhibitor‐bound human 5‐lipoxygenase‐activating protein. Science 317: 510–512.

Flamand N, Luo M, Peters‐Golden M et al. (2009) Phosphorylation of serine 271 on 5‐lipoxygenase and its role in nuclear export. Journal of Biological Chemistry 284: 306–313.

Flamand N, Surette ME, Picard S et al. (2002) Cyclic AMP‐mediated inhibition of 5‐lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Molecular Pharmacology 62: 250–256.

Gilbert NC, Bartlett SG, Waight MT et al. (2011) The structure of human 5‐lipoxygenase. Science 331: 217–219.

Gilbert NC, Rui Z, Neau DB et al. (2012) Conversion of human 5‐lipoxygenase to a 15‐lipoxygenase by a point mutation to mimic phosphorylation at Serine‐663. FASEB Journal 26: 3222–3229.

Gillmor SA, Villasenor A, Fletterick R et al. (1997) The structure of mammalian 15‐lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nature Structural & Molecular Biology 4: 1003–1009.

Häfner AK, Cernescu M, Hofmann B et al. (2011) Dimerization of human 5‐lipoxygenase. Biological Chemistry 392: 1097–1111.

Hammarberg T, Provost P, Persson B et al. (2000) The N‐terminal domain of 5‐lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. Journal of Biological Chemistry 275: 38787–38793.

Hammarberg T and Radmark O (1999) 5‐Lipoxygenase binds calcium. Biochemistry 38: 4441–4447.

Hanaka H, Shimizu T and Izumi T (2005) Stress‐induced nuclear export of 5‐lipoxygenase. Biochemical and Biophysical Research Communications 338: 111–116.

Hofheinz K, Kakularam KR, Adel S et al. (2013) Conversion of pro‐inflammatory murine Alox5 into an anti‐inflammatory 15S‐lipoxygenating enzyme by multiple mutations of sequence determinants. Archives of Biochemistry and Biophysics 530: 40–47.

Hornig C, Albert D, Fischer L et al. (2005) 1‐Oleoyl‐2‐acetylglycerol stimulates 5‐lipoxygenase activity via a putative (phospho)lipid binding site within the N‐terminal C2‐like domain. Journal of Biological Chemistry 280: 26913–26921.

Kulkarni S, Das S, Funk CD et al. (2002) A molecular basis of specific subcellular localization of the C2‐like domain of 5‐lipoxygenase. Journal of Biological Chemistry 277: 13167–13174.

Luo M, Jones SM, Flamand N et al. (2005) Phosphorylation by protein kinase a inhibits nuclear import of 5‐lipoxygenase. Journal of Biological Chemistry 280: 40609–40616.

Luo M, Jones SM, Peters‐Golden M et al. (2003) Nuclear localization of 5‐lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proceedings of the National Academy of Sciences of the USA 100: 12165–12170.

Luo M, Jones SM, Phare SM et al. (2004) Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5‐lipoxygenase on serine 523. Journal of Biological Chemistry 279: 41512–41520.

Mandal AK, Jones PB, Bair AM et al. (2008) The nuclear membrane organization of leukotriene synthesis. Proceedings of the National Academy of Sciences of the USA 105: 20434–20439.

Markoutsa S, Sürun D, Karas M et al. (2014) Analysis of 5‐lipoxygenase phosphorylation on molecular level by MALDI‐MS. FEBS Journal 281(8) :1931–1947.

Murphy RC, Hammarström S and Samuelsson B (1979) Leukotriene C: a slow reacting substance from murine mastocytoma cells. Proceedings of the National Academy of Sciences of the USA 76: 4275–4279.

Newcomer ME and Gilbert NC (2010) Location, location, location: compartmentalization of early events in leukotriene biosynthesis. Journal of Biological Chemistry 285: 25109–25114.

Okamoto H, Hammarberg T, Zhang YY et al. (2005) Mutation analysis of the human 5‐lipoxygenase C‐terminus: support for a stabilizing C‐terminal loop. Biochimica et Biophysica Acta 1749: 123–131.

Pande AH, Qin S and Tatulian SA (2005) Membrane fluidity is a key modulator of membrane binding, insertion, and activity of 5‐lipoxygenase. Biophysics Journal 88: 4084–4094.

Pergola C, Dodt G, Rossi A et al. (2008) ERK‐mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proceedings of the National Academy of Sciences of the USA 105: 19881–19886.

Pergola C, Rogge A, Dodt G et al. (2011) Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. FASEB Journal 25: 3377–3387.

Plante H, Picard S, Mancini J et al. (2006) 5‐lipoxygenase‐activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. Biochemical Journal 393: 211–218.

Provost P, Dishart D, Doucet J et al. (2002) Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO Journal 21: 5864–5874.

Provost P, Doucet J, Hammarberg T et al. (2001a) 5‐Lipoxygenase interacts with coactosin‐like protein. Journal of Biological Chemistry 276: 16520–16527.

Provost P, Doucet J, Stock A et al. (2001b) Coactosin‐like protein, a human F‐actin‐binding protein: critical role of lysine‐75. Biochemical Journal 359: 255–263.

Provost P, Samuelsson B and Rådmark O (1999) Interaction of 5‐lipoxygenase with cellular proteins. Proceedings of the National Academy of Sciences of the USA 96: 1881–1885.

Rådmark O, Werz O, Steinhilber D et al. (2007) 5‐Lipoxygenase: regulation of expression and enzyme activity. Trends in Biochemical Sciences 32: 332–341.

Rakonjac M, Fischer L, Provost P et al. (2006) Coactosin‐like protein supports 5‐lipoxygenase enzyme activity and up‐regulates leukotriene A4 production. Proceedings of the National Academy of Sciences of the USA 103: 13150–13155.

Rakonjac Ryge M, Tanabe M, Provost P et al. (2014). A mutation interfering with 5‐lipoxygenase domain interaction leads to increased enzyme activity. Archives of Biochemistry and Biophysics 545: 179–185.

Walther M, Hofheinz K, Vogel R et al. (2011) The N‐terminal beta‐barrel domain of mammalian lipoxygenases including mouse 5‐lipoxygenase is not essential for catalytic activity and membrane binding but exhibits regulatory functions. Archives of Biochemistry and Biophysics 516: 1–9.

Werz O, Bürkert E, Fischer L et al. (2002a) Extracellular signal‐regulated kinases phosphorylate 5‐lipoxygenase and stimulate 5‐lipoxygenase product formation in leukocytes. FASEB Journal 16: 1441–1443.

Werz O, Bürkert E, Rådmark O et al. (2002b) Activation of 5‐lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99: 1044–1052.

Werz O, Klemm J, Samuelsson B et al. (2001) Phorbol ester up‐regulates capacities for nuclear translocation and phosphorylation of 5‐lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood 97: 2487–2495.

Werz O and Steinhilber D (2005) Development of 5‐lipoxygenase inhibitors – Lessons from cellular enzyme regulation. Biochemical Pharmacology 70: 327–333.

Zhang YY, Hammarberg T, Rådmark O et al. (2000) Analysis of a nucleotide‐binding site of 5‐lipoxygenase by affinity labelling: binding characteristics and amino acid sequences. Biochemical Journal 351: 697–707.

Further Reading

Evans JF, Ferguson AD, Mosley RT et al. (2008) What's all the FLAP about? 5‐Lipoxygenase‐activating protein inhibitors for inflammatory diseases. Trends in Pharmacological Sciences 29: 72–78.

Jakobsson PJ, Morgenstern R, Mancini J et al. (2000) Membrane‐associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. American Journal of Respiratory and Critical Care Medicine 161: S20–S24.

Lam BK, Penrose JF, Xu K et al. (1995) Leukotriene C4 synthase. Journal of Lipid Mediators and Cell Signalling 12: 333–341.

Pergola C and Werz O (2010) 5‐Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opinion on Therapeutic Patents 20: 355–375.

Perron MP and Provost P (2009) Protein components of the microRNA pathway and human diseases. Methods in Molecular Biology 487: 369–385.

Powell WS and Rokach J (2005) Biochemistry, biology and chemistry of the 5‐lipoxygenase product 5‐oxo‐ETE. Progress in Lipid Research 44: 154–183.

Rådmark O (2002) Arachidonate 5‐lipoxygenase. Prostaglandins & Other Lipid Mediators 68–69: 211–234.

Rådmark O and Samuelsson B (2010) Regulation of the activity of 5‐lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochemical and Biophysical Research Communications 396: 105–110.

Samuelsson B, Dahlén S‐E, Lindgren J‐Å et al. (1987) Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237: 1171–1176.

Werz O (2002) 5‐Lipoxygenase: Cellular Biology and Molecular Pharmacology. Current Drug Targets 1: 23–44.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Werz, Oliver, Rådmark, Olof, and Steinhilber, Dieter(Oct 2014) Recent Advances on 5‐Lipoxygenase Biochemistry. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0024630]